Treatment of depressive symptoms in patients after coronary artery bypass graft surgery
Phase 3
Recruiting
- Conditions
- Depression.Major depressive disorder, single episode, mildF32.0
- Registration Number
- IRCT20190525043700N2
- Lead Sponsor
- Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Coronary artery bypass graft surgery
Willingness to participate in the study
Exclusion Criteria
Patient with cognitive impairment
Mental retardation
History of substance use
Bipolar disorder
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient´s depressive condition. Timepoint: Before intervention (first visit) ,the end of the fourth week (second visit),the end of the eighth week (third visit). Method of measurement: Beck Depression Questionnaire.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bupropion's antidepressant effects in post-CABG depression compared to S-citalopram?
How does bupropion compare to S-citalopram in remission rates for F32.0 depression after coronary artery bypass surgery?
Which biomarkers predict differential response to bupropion versus S-citalopram in post-cardiac surgery patients?
What adverse events are associated with bupropion use in IRCT20190525043700N2 compared to standard SSRIs?
Are SNRIs like bupropion more effective than SSRIs for managing post-CABG depression with specific neuroinflammatory profiles?